Key Points
- Insider sale: USANA Health Sciences insider Joshua Foukas sold 3,791 shares on May 7 at an average price of $19.82, totaling about $75,138. He also sold 4,461 shares in February at $21.34.
- Strong quarterly results: The company reported Q1 EPS of $0.61, beating analyst estimates of $0.44, while revenue of $250.22 million also topped expectations. USANA raised its FY2026 guidance to 1.950–2.290 EPS.
- Mixed market sentiment: Despite the earnings beat and some upbeat analyst revisions, recent ratings activity has been cautious, with multiple firms downgrading the stock and MarketBeat showing an average rating of “Reduce.”
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider Joshua Foukas sold 3,791 shares of the firm's stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $19.82, for a total transaction of $75,137.62. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Joshua Foukas also recently made the following trade(s):
- On Friday, February 20th, Joshua Foukas sold 4,461 shares of USANA Health Sciences stock. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74.
USANA Health Sciences Price Performance
NYSE USNA opened at $19.00 on Friday. USANA Health Sciences, Inc. has a 12 month low of $16.60 and a 12 month high of $38.32. The company has a market capitalization of $350.74 million, a P/E ratio of 40.43, a PEG ratio of 0.76 and a beta of 0.77. The company's 50 day simple moving average is $18.45 and its 200 day simple moving average is $19.70.
USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.17. The firm had revenue of $250.22 million during the quarter, compared to analysts' expectations of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.
Hedge Funds Weigh In On USANA Health Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in USNA. National Bank of Canada FI grew its position in USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company's stock worth $53,000 after purchasing an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after purchasing an additional 1,901 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of USANA Health Sciences by 52.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company's stock worth $106,000 after buying an additional 1,327 shares during the period. Parallel Advisors LLC boosted its position in shares of USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company's stock worth $76,000 after buying an additional 3,589 shares during the period. Finally, Quantbot Technologies LP grew its holdings in shares of USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock valued at $121,000 after buying an additional 646 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company's stock.
More USANA Health Sciences News
Here are the key news stories impacting USANA Health Sciences this week:
Analyst Ratings Changes
USNA has been the topic of a number of recent research reports. Zacks Research cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 22nd. Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Finally, Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, USANA Health Sciences currently has an average rating of "Reduce".
View Our Latest Stock Analysis on USNA
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
